<DOC>
	<DOC>NCT00351546</DOC>
	<brief_summary>Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vildagliptin on insulin sensitivity in people with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes at least 3 months prior to screening Blood glucose criteria must be met On stable dose of metformin therapy BMI less than or equal to 39 Type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes Treatment with thiazolidinediones or use of insulin within the previous 3 months Significant illness within 2 weeks prior to dosing High fasting triglycerides as defined by the protocol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Insulin action</keyword>
</DOC>